https://doi.org/10.18773/austprescr.2020.075
This is what the Australian Government currently pays towards medications.
Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. Let them go blind or die of bowel cancer seems to be your preferred option.
Then we have all the checkpoint inhibitors. Let them die of melanoma. After all they bought it on themselves for not slip/slop/slapping.
How many 'little kiddies' can we then feed overseas with that money? 'So, before you spout you sanctimonious dribble' about supplying fresh water and food to the millions overseas, know the facts about how much we already pay to give our residents in this country a better life.
- Forums
- ASX - By Stock
- Ann: COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT
https://doi.org/10.18773/austprescr.2020.075This is what the...
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.46 |
Change
-0.035(2.35%) |
Mkt cap ! $1.689B |
Open | High | Low | Value | Volume |
$1.57 | $1.58 | $1.41 | $9.630M | 6.426M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 28093 | $1.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.46 | 24665 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 16500 | 1.435 |
8 | 26223 | 1.430 |
9 | 31937 | 1.425 |
8 | 75480 | 1.420 |
7 | 95704 | 1.415 |
Price($) | Vol. | No. |
---|---|---|
1.440 | 11693 | 3 |
1.445 | 43216 | 6 |
1.450 | 143280 | 6 |
1.455 | 2744 | 2 |
1.460 | 10009 | 3 |
Last trade - 11.16am 07/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
MSB (ASX) Chart |